Physician profile
Manisha Korb
NPI 1235494089
$328,008.91
in general payments reported to CMS, 2019-2025
33 companies · $57K in 2025
The $57K reported for 2025 was more than what 94% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $20K · 2021: $23K · 2022: $73K · 2023: $53K · 2024: $45K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Consulting Fee: $15K · Travel and Lodging: $12K · Food and Beverage: $5,762 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,982.03 |
| Consulting Fee | $15,224.00 |
| Travel and Lodging | $12,397.42 |
| Food and Beverage | $5,761.80 |
| Education | $218.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $227,545.00 | 2019-2025 | Spinraza, Spinraza, Qalsody |
| Genentech USA, INC. | $68,721.34 | 2022-2025 | Evrysdi, Ocrevus Zunovo |
| Argenx US, INC. | $12,046.33 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $5,121.90 | 2019-2023 | Hizentra |
| Alexion Pharmaceuticals, INC. | $4,433.27 | 2019-2025 | Ultomiris |
| F. Hoffmann-La Roche Ag | $2,877.22 | 2024-2025 | |
| Genentech, INC. | $2,686.97 | 2021-2024 | Evrysdi |
| Grifols USA, LLC | $2,589.83 | 2022-2023 | Gamunex-C |
| Janssen Biotech, INC. | $544.52 | 2025 | |
| Ucb, INC. | $252.66 | 2024-2025 | Rystiggo, Briviact, Zilbrysq |
| Eisai INC. | $187.91 | 2025 | |
| Abbvie INC. | $183.24 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $122.97 | 2021-2024 | Amvuttra |
| Teva Pharmaceuticals USA, INC. | $105.96 | 2025 | Austedo Xr |
| Amgen INC. | $83.43 | 2024-2025 | Uplizna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $58.27 | 2025 | Nuplazid |
| Grifols Shared Services North America, INC. | $57.67 | 2019 | |
| Merz Pharmaceuticals, LLC | $55.94 | 2023 | Xeomin |
| Mallinckrodt Hospital Products INC. | $42.56 | 2025 | Acthar |
| Sarepta Therapeutics, INC. | $32.05 | 2024 | Elevidys |
| Lundbeck LLC | $31.88 | 2025 | Vyepti |
| Sk Life Science, INC. | $28.74 | 2025 | |
| Scilex Pharmaceuticals INC. | $24.76 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.39 | 2025 | Hyqvia |
| Catalyst Pharmaceuticals, INC. | $23.09 | 2025 | |
| Springworks Therapeutics, INC. | $21.78 | 2025 | Gomekli |
| Tanabe Pharma America, INC. | $20.74 | 2019 | |
| Emd Serono, INC. | $17.70 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2025 | Rexulti |
| Lilly USA, LLC | $17.22 | 2024 | Kisunla |
| Genzyme Corporation | $16.10 | 2023 | |
| Neurelis, INC. | $14.97 | 2024 | Valtoco |
| Travere Therapeutics, INC. | $0.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Korb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.